| 摘要 |
PROBLEM TO BE SOLVED: To provide a pharmaceutical composition facilitating the administration of pranlukast hydrate by reducing the bitterness of the pranlukast hydrate, and enabling the rapid absorption of the pranlukast hydrate into the body. SOLUTION: The pharmaceutical composition contains the pranlukast hydrate having 1-15μm average particle diameter and saccharides having 5-150μm average particle diameter and 0.05-6 wt.% water content. The pharmaceutical composition exhibits one or more characteristics of the following (1) to (3) when a unit dose containing 225 mg pranlukast hydrate is orally administered, and the bitterness of the pranlukast hydrate is reduced: (1) the time for achieving the maximum concentration in the plasma is within 6 hr after the oral administration; (2) the maximum concentration in the plasma is≥500 ng/mL; and (3) the time for achieving 100 ng/mL concentration in the plasma is within 3 hr. COPYRIGHT: (C)2008,JPO&INPIT
|
